Spots Global Cancer Trial Database for Neoadjuvant Nivolumab in Glioblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Nivolumab in Glioblastoma
Official Title: Phase II Study of Neoadjuvant Nivolumab in Patients With Glioblastoma Multiforme
Study ID: NCT02550249
Conditions
Interventions
Study Description
Brief Summary: Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery.
Detailed Description: Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery until toxicity or progression.
Keywords
Eligibility
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Clinica Universidad de Navarra, Pamplona, Navarra, Spain
Contact Details
Name: Ignacio Melero, MD, PhD
Affiliation: Clinica Universidad de Navarra
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
